<code id='B000622BF3'></code><style id='B000622BF3'></style>
    • <acronym id='B000622BF3'></acronym>
      <center id='B000622BF3'><center id='B000622BF3'><tfoot id='B000622BF3'></tfoot></center><abbr id='B000622BF3'><dir id='B000622BF3'><tfoot id='B000622BF3'></tfoot><noframes id='B000622BF3'>

    • <optgroup id='B000622BF3'><strike id='B000622BF3'><sup id='B000622BF3'></sup></strike><code id='B000622BF3'></code></optgroup>
        1. <b id='B000622BF3'><label id='B000622BF3'><select id='B000622BF3'><dt id='B000622BF3'><span id='B000622BF3'></span></dt></select></label></b><u id='B000622BF3'></u>
          <i id='B000622BF3'><strike id='B000622BF3'><tt id='B000622BF3'><pre id='B000622BF3'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:1129
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand. Adobe

          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

          advertisement

          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          Akili changes sales model for its ADHD video game treatment
          Akili changes sales model for its ADHD video game treatment

          AdobeAkiliInteractive,whichin2020madewavesbyreceivingFoodandDrugAdministrationclearanceforitsvideoga

          read more
          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more

          PBMs drew scrutiny in House hearing — and so did pharma

          Rep.JamesComer,chairoftheHouseOversightCommitteeKevinDietsch/GettyImagesWASHINGTON—Congresswantstore